|drug2711||QazCovid-in®-vaccine against COVID-19 Wiki||1.00|
|drug2529||Placebo Vaccine Wiki||0.71|
|D045169||Severe Acute Respiratory Syndrome NIH||0.20|
|D018352||Coronavirus Infections NIH||0.16|
There is one clinical trial.
The objective is to determine the safety and immunogenicity of two different strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to demonstrate the safety and efficacy in prophylaxis of COVID-19.
Description: The number and proportion of subjects with adverse events observed until Day 43 post 1st vaccination are declared to be primary target variables.Measure: To assess the safety and tolerability of the COVID-19 vaccine Time: 43 days
Description: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s).Measure: Specific antibody response induced by the vaccine against the SARS-CoV-2 virus Time: 12 months
Description: Serum Neutralizing antibody levels.Measure: Neutralizing Antibodies Levels Time: 12 months
Description: Serum TNF-alpha levels.Measure: TNF-alpha Levels Time: 12 months
Description: Serum IFN-γ levels.Measure: Interferon Levels Time: 12 months
Description: Serum IL-2, -4, -5, -6 levels.Measure: Interleukine Levels Time: 12 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports